User talk:PriorAuthPaz

Your run of edits through Prior authorisation and Glucagon-like peptide-1 tidied up an inconsistency that had been bothering me for a while: the two articles were quoting the same figure under different definitions. Thank you for reconciling them rather than just picking one. — TierTwoTansy (talk) 12:34, 7 April 2025 (UTC)

Thank you. Reconciling them meant going back to both sources, which took longer than picking one but is the only honest way to do it. — PriorAuthPaz (talk) 02:23, 8 April 2025 (UTC)

The prices in Prior authorisation carry neither a currency nor a date, and one of them is plainly a list price while its neighbour is plainly not. Do you have the source? A price without a date ages badly and a price without a currency is not a price. — DisparityDagny (talk) 18:31, 9 April 2025 (UTC)

Both added. One of the two was indeed a list price and is now labelled as such. — PriorAuthPaz (talk) 16:52, 10 April 2025 (UTC)

The cost paragraph in Peptide harm reduction reads as an argument rather than a description. The figures are sound; it is the connective tissue between them that is doing the arguing. I have cut the connectives and left the figures, which make the point on their own. — CostPerMgCory (talk) 15:50, 7 October 2025 (UTC)

Agreed. Cutting the connectives left a shorter paragraph that argues less and shows more. — PriorAuthPaz (talk) 21:03, 7 October 2025 (UTC)